X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43 - thereby improving synaptic transmission, axonal transport and neuroinflammation in patients with Alzheimer’s Disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being evaluated for the treatment of patients with mild to moderate Alzheimer’s disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
ANVS401 (buntanetap) works by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being developed for mild to moderate Alzheimer’s disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
ANVS401 (Buntanetap) is a novel small molecule TINAPs Inhibitor which is currently being evaluated in phase 3 clinical trials of the treatment of Parkinson's Disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being evaluated for the treatment of Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
ANVS402 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS402
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Annovis will fund the clinical development of Annovis’ lead drug candidate, ANVS402 a crystallized formulation of buntanetap, including the conduct of Annovis’ on-going and planned clinical trials.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS402
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 31, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Buntanetap (ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Buntanetap (previously known as ANVS401 or posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: Posiphen
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to lower levels of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to lower levels of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to lower levels of neurotoxic proteins and consequently less toxicity in the brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in brain.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The Company will use the net proceeds from the offering primarily for general corporate purposes, including working capital, R&D , capital expenditures and the completion of its planned Phase 3 clinical trial for ANVS401 in AD in persons with Down Syndrome.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 27, 2021
Details:
The study compares in both patient populations how nerve cells die by measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401 might reverse the toxic cascade and recover normal brain function.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The studies are designed to treat a combined total of 28 AD and PD patients for four weeks with Annovis' lead compound, ANVS401.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Annovis Bio has received clearance from the Central Institutional Review Board to launch its Phase 2 clinical trial in patients with early PD and early AD. The two-part study aims to treat a net number of 68 PD and AD patients with Annovis' lead drug, ANVS401 for 4 weeks.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Annovis Bio completed the rat cohort of a chronic toxicology study of its lead drug ANVS401, reporting no negative side effects. The safety seen in the rats corroborates the positive results from the Company’s prior 1 month safety studies in mice, rats, dogs, and humans.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
European Patent Office (EPO) granted the Company’s patent for a method of treating Alzheimer’s disease in humans by administering its lead compound, ANVS401.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Annovis Bio filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via by ANVS401 or related compounds.
Lead Product(s): Buntanetap
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
Annovis Bio plans to proceed with a two-part study designed to treat a combined total of 68 Alzheimer’s and Parkinson’s patients for one month with Annovis’ compound, ANVS401.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
The grant supports company’s long-term toxicology studies in rats and in dogs of its lead therapeutic compound ANVS401.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding February 27, 2020
Details:
Data Safety Monitoring Board has unanimously supported that the study, which is named DISCOVER, continue without modification.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
